WO1991015208A1 - Veterinary treatment - Google Patents
Veterinary treatment Download PDFInfo
- Publication number
- WO1991015208A1 WO1991015208A1 PCT/GB1991/000442 GB9100442W WO9115208A1 WO 1991015208 A1 WO1991015208 A1 WO 1991015208A1 GB 9100442 W GB9100442 W GB 9100442W WO 9115208 A1 WO9115208 A1 WO 9115208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- veterinarily acceptable
- amoxycillin
- lambs
- treatment
- clavulanic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a method for the treatment of pneumonic pasteurellosis in animals, particularly in lambs and sheep.
- GB-B-2 005 538 describes a dry pharmaceutical composition, which comprises 20mg to 1500mg of amoxycillin trihydrate, 20mg to 500mg of potassium clavulanate and a pharmaceutically acceptable carrier, with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to 1:1.
- a method for the treatment of pneumonic pasteurellosis in lambs or sheep which comprises administering to the animal an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.
- a second aspect of the invention provides the use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier in the manufacture of a medicament for use in the treatment of pneumonic pasteurellosis in lambs or sheep.
- the formulation has notable bactericidal activity against the bacteria associated with the disease pneumonic pasteurellosis, in particular P.haemolvtica.
- the clavulanic acid used in the formulation is in the form of a veterinarily acceptable salt such as potassium clavulanate.
- amoxycillin used in the formulation is in the form of the trihydrate or a veterinarily acceptable ester or salt of amoxycillin such as the sodium salt.
- the preferred weight ratio of amoxycillin or derivative to clavulanic acid or derivative is from 6:1 to 1:1.
- a liquid formulation of the invention comprises 36mg/ml clavulanic acid (as potassium clavulanate) and 140mg/ml amoxycillin (as amoxycillin trihydrate) .
- Preferred veterinarily acceptable carriers include for example veterinarily acceptable oils such as mineral oils or fractionated coconut oil such as Miglyol 840.
- the formulation is administered to the animal by intramuscular injection.
- the formulation is typically prepared as an off-white suspension and is presented as a 'Ready-To-Use' form, that is the formulation is preprepared and packed in a suitable container, wherein it is ready for administration to the animal in need thereof.
- the dosage rate will vary according to the size of the animal.
- a suitable dosage rate is generally between 2 and 25mg/kg bodyweight of the animal, for example about lOmg/kg.
- a single dose of the formulation will be required for the treatment of pneumonic pasteurellosis, suitably one dose per day for 3 to 5 days is required. In cases of severe infections prolonged treatment may be
- Veterinary formulations for use in the present invention may be prepared by mixing the ingredients in the required proportions.
- the formulation is then packaged into an appropriate container ready for administration.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Soil Working Implements (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A formulation comprising amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier is used in the treatment of pneumonic pasteurellosis in lambs or sheep.
Description
Veterinary Treatment
This invention relates to a method for the treatment of pneumonic pasteurellosis in animals, particularly in lambs and sheep.
GB-B-2 005 538 describes a dry pharmaceutical composition, which comprises 20mg to 1500mg of amoxycillin trihydrate, 20mg to 500mg of potassium clavulanate and a pharmaceutically acceptable carrier, with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to 1:1.
According to the present invention there is provided a method for the treatment of pneumonic pasteurellosis in lambs or sheep, which comprises administering to the animal an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.
A second aspect of the invention provides the use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier in the manufacture of a medicament for use in the treatment of pneumonic pasteurellosis in lambs or sheep.
The formulation has notable bactericidal activity against the bacteria associated with the disease pneumonic pasteurellosis, in particular P.haemolvtica.
Suitably the clavulanic acid used in the formulation is in the form of a veterinarily acceptable salt such as potassium clavulanate.
SUBSTITUTE SHEET
Suitably the amoxycillin used in the formulation is in the form of the trihydrate or a veterinarily acceptable ester or salt of amoxycillin such as the sodium salt.
The preferred weight ratio of amoxycillin or derivative to clavulanic acid or derivative is from 6:1 to 1:1.
Advantageously, a liquid formulation of the invention comprises 36mg/ml clavulanic acid (as potassium clavulanate) and 140mg/ml amoxycillin (as amoxycillin trihydrate) .
Preferred veterinarily acceptable carriers include for example veterinarily acceptable oils such as mineral oils or fractionated coconut oil such as Miglyol 840.
Suitably the formulation is administered to the animal by intramuscular injection.
The formulation is typically prepared as an off-white suspension and is presented as a 'Ready-To-Use' form, that is the formulation is preprepared and packed in a suitable container, wherein it is ready for administration to the animal in need thereof.
The dosage rate will vary according to the size of the animal. A suitable dosage rate is generally between 2 and 25mg/kg bodyweight of the animal, for example about lOmg/kg.
Typically more than a single dose of the formulation will be required for the treatment of pneumonic pasteurellosis, suitably one dose per day for 3 to 5 days is required. In cases of severe infections prolonged treatment may be
SUBSTITUTESHEET
required.
Veterinary formulations for use in the present invention may be prepared by mixing the ingredients in the required proportions.
The formulation is then packaged into an appropriate container ready for administration.
The following Example illustrates the invention.
SUBSTITUTESHEET
Formulation
amoxycillin trihydrate potassium clavulanate phenol Miglyol 840
SUBSTITUTE SHEET
Biological data
1. Twenty 3-week old specific-pathogen-free Suffolk cross lambs were infected experimentally with an amoxycillin-sensitive strain of Pasteurella haemolvtica, type A at a concentration of 7.43 x 10 colony forming units per litre of air per minute.
2. Ten of the lambs received the formulation shown above by intramuscular injection at the recommended dose of lml/20Kg. of bodyweight. The treatment was repeated 24 and 48 hours later. The remaining ten lambs received no treatment.
3. Treated and untreated lambs were examined clinically for 7 days after infection when the survivors were necropsied. The results of the clinical findings are summarised in Table I.
4. One of the ten treated lambs died 6 days after infection. Seven of the ten untreated lambs died 3 (4 lambs) 4 (1 lamb) 5 (1 lamb) and 6 (1 lamb) days after infection. This difference in death rates was significant (p< 0.01 Fischer's Extract Test). In the treated group clinical abnormalities were present only in the lamb which died and that was on the day of the first treatment with the formulation.
5. Clinical abnormalities were found in 9 of the 10 untreated lambs. These clinical abnormalities and necropsy findings were similar to those expected during outbreaks of acute pastuerellosis in lambs of similar age under farm conditions. All those lambs which died had bacteriological evidence of pasteurellosis and showed either pleurisy or a subacute pneumonia consistent with Pastuerella haemolvtica type A infection.
SUBSTITUTESHEET
ND = not done
It is concluded that there was a significant effect on the animals that were treated, and that the formulation has good efficacy in the treatment of pneumonic pasteurellosis in sheep.
SUBSTITUTESHEET
Claims
1. The use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier in the manufacture of a medicament for use in the treatment of pneumonic pasteurellosis in lambs or sheep.
2. A method for the treatment of pneumonic pasteurellosis in lambs or sheep, which comprises administering to the animal an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.
3. A composition for the treatment of pneumonic pasteurellosis in lambs or sheep, which comprises an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.
. The use according to claim 1 wherein amoxycillin is used as the trihydrate or sodium salt.
5. The use according to claim 1 or 4 wherein clavulanic acid is used as the potassium salt.
6. The use according to claim 1, 4 or 5 wherein the carrier is an oil suitable for injection.
7. The use according to claim 1, 4, 5 or 6 wherein the amoxycillin or its derivative and the clavulanic acid or its derivative are in a weight ratio of 6:1 to 1:1.
SUBSTITUTESHEET
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002079328A CA2079328C (en) | 1990-03-30 | 1991-03-25 | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof |
| DE69117943T DE69117943T2 (en) | 1990-03-30 | 1991-03-25 | TREATMENT OF ANIMALS |
| AU75708/91A AU648787B2 (en) | 1990-03-30 | 1991-03-25 | Veterinary treatment of lambs and sheep |
| EP91906802A EP0521974B1 (en) | 1990-03-30 | 1991-03-25 | Veterinary treatment |
| JP3506949A JP3032904B2 (en) | 1990-03-30 | 1991-03-25 | Veterinary treatment methods |
| KR1019920702371A KR100190869B1 (en) | 1990-03-30 | 1992-09-29 | Veterinary treatment |
| GR960401563T GR3020197T3 (en) | 1990-03-30 | 1996-06-12 | Veterinary treatment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9007143.2 | 1990-03-30 | ||
| GB909007143A GB9007143D0 (en) | 1990-03-30 | 1990-03-30 | Veterinary composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991015208A1 true WO1991015208A1 (en) | 1991-10-17 |
Family
ID=10673543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1991/000442 WO1991015208A1 (en) | 1990-03-30 | 1991-03-25 | Veterinary treatment |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0521974B1 (en) |
| JP (1) | JP3032904B2 (en) |
| KR (1) | KR100190869B1 (en) |
| AT (1) | ATE135213T1 (en) |
| AU (1) | AU648787B2 (en) |
| CA (1) | CA2079328C (en) |
| DE (1) | DE69117943T2 (en) |
| DK (1) | DK0521974T3 (en) |
| ES (1) | ES2085990T3 (en) |
| GB (1) | GB9007143D0 (en) |
| GR (1) | GR3020197T3 (en) |
| IE (1) | IE71191B1 (en) |
| NZ (1) | NZ237615A (en) |
| WO (1) | WO1991015208A1 (en) |
| ZA (1) | ZA912369B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9009446D0 (en) * | 1990-04-26 | 1990-06-20 | Beecham Group Plc | Veterinary composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336130A1 (en) * | 1975-04-14 | 1977-07-22 | Beecham Group Ltd | Antibacterial deoxy-clavulanic and isodeoxy-clavulanic acids - antibacterials used in treating urinary tract infections respiratory, illness, non-muscular tissue infections etc. |
| EP0010904A2 (en) * | 1978-10-27 | 1980-05-14 | Beecham Group Plc | Intramammary compositions and process for their preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | K-clavulanate/tri hydrate formulations |
| GB9009446D0 (en) * | 1990-04-26 | 1990-06-20 | Beecham Group Plc | Veterinary composition |
-
1990
- 1990-03-30 GB GB909007143A patent/GB9007143D0/en active Pending
-
1991
- 1991-03-25 JP JP3506949A patent/JP3032904B2/en not_active Expired - Fee Related
- 1991-03-25 AU AU75708/91A patent/AU648787B2/en not_active Ceased
- 1991-03-25 DK DK91906802.3T patent/DK0521974T3/en active
- 1991-03-25 AT AT91906802T patent/ATE135213T1/en not_active IP Right Cessation
- 1991-03-25 CA CA002079328A patent/CA2079328C/en not_active Expired - Fee Related
- 1991-03-25 EP EP91906802A patent/EP0521974B1/en not_active Expired - Lifetime
- 1991-03-25 DE DE69117943T patent/DE69117943T2/en not_active Expired - Fee Related
- 1991-03-25 WO PCT/GB1991/000442 patent/WO1991015208A1/en active IP Right Grant
- 1991-03-25 ES ES91906802T patent/ES2085990T3/en not_active Expired - Lifetime
- 1991-03-28 ZA ZA912369A patent/ZA912369B/en unknown
- 1991-03-28 NZ NZ237615A patent/NZ237615A/en unknown
- 1991-03-28 IE IE107491A patent/IE71191B1/en not_active IP Right Cessation
-
1992
- 1992-09-29 KR KR1019920702371A patent/KR100190869B1/en not_active IP Right Cessation
-
1996
- 1996-06-12 GR GR960401563T patent/GR3020197T3/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336130A1 (en) * | 1975-04-14 | 1977-07-22 | Beecham Group Ltd | Antibacterial deoxy-clavulanic and isodeoxy-clavulanic acids - antibacterials used in treating urinary tract infections respiratory, illness, non-muscular tissue infections etc. |
| EP0010904A2 (en) * | 1978-10-27 | 1980-05-14 | Beecham Group Plc | Intramammary compositions and process for their preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2085990T3 (en) | 1996-06-16 |
| DE69117943T2 (en) | 1996-08-01 |
| GR3020197T3 (en) | 1996-09-30 |
| DK0521974T3 (en) | 1996-04-15 |
| JP3032904B2 (en) | 2000-04-17 |
| JPH05505818A (en) | 1993-08-26 |
| EP0521974B1 (en) | 1996-03-13 |
| AU648787B2 (en) | 1994-05-05 |
| AU7570891A (en) | 1991-10-30 |
| NZ237615A (en) | 1992-01-29 |
| CA2079328A1 (en) | 1991-10-01 |
| EP0521974A1 (en) | 1993-01-13 |
| KR930700098A (en) | 1993-03-13 |
| ZA912369B (en) | 1992-02-26 |
| IE911074A1 (en) | 1991-10-09 |
| CA2079328C (en) | 2002-01-29 |
| GB9007143D0 (en) | 1990-05-30 |
| DE69117943D1 (en) | 1996-04-18 |
| IE71191B1 (en) | 1997-02-12 |
| ATE135213T1 (en) | 1996-03-15 |
| KR100190869B1 (en) | 1999-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5258372A (en) | Tetracycline activity enhancement using doxycycline or sancycline | |
| Wolff et al. | Efficacy of triclabendazole against Fasciola hepatica in sheep and goats | |
| EP0126145A1 (en) | Tetracycline activity enhancement. | |
| Touraki et al. | Bioaccumulation of trimethoprim, sulfamethoxazole and N-acetyl-sulfamethoxazole in Artemia nauplii and residual kinetics in seabass larvae after repeated oral dosing of medicated nauplii | |
| US4772460A (en) | Method of reducing the swelling or pain associated with antibiotics compositions | |
| DE69717988T2 (en) | TOPICAL ADMINISTRATION OF PREMAFLOXACIN FOR TREATING SYSTEMIC BACTERIAL DISEASES | |
| DK153123B (en) | METHOD FOR PREPARING A POWDER-PHARMACEUTICAL PREPARATION CONTAINING AMOXYCILLIN TRIHYDRATE | |
| NZ198878A (en) | Intramammal anti-mastitis preparation containing a 6beta halopenicillanic acid derivative together with one or more beta-lactam antibiotics | |
| CA2079328C (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
| Khalil et al. | Ceftiofur pharmacokinetics in Nile tilapia Oreochromis niloticus after intracardiac and intramuscular administrations | |
| US4997830A (en) | Pharmaceutical composition for the treatment of periodontitis | |
| AU648792B2 (en) | Veterinary treatment for pigs | |
| EP0238207B1 (en) | Bactericidal mixtures | |
| Guillot et al. | Chloramphenicol and oxytetracycline residues in milk and tissues from cows and bullocks treated with an injectable formulation | |
| US5643902A (en) | Veterinary treatment | |
| KR102058133B1 (en) | Composition for enhancing immune activity capable of improving of solubility of antibiotics in mixed formulation and use thereof | |
| IE83642B1 (en) | Veterinary treatment | |
| IE921419A1 (en) | Treatment of mastitis | |
| CN1238687A (en) | An oil composition of dihydropolyprenols | |
| Fu et al. | Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice | |
| JPH11501904A (en) | Pharmaceutical formulation comprising clavulanic acid salt, vancomycin and one or more beta-lactam antibiotics | |
| JPS61165332A (en) | Preventive or remedy for mycoplasmosis of domestic animal and swine dysentery | |
| JPH07103036B2 (en) | Method for preventing and treating nodular disease of fish |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991906802 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2079328 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991906802 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1991906802 Country of ref document: EP |